Acadia Pharmaceuticals (ACAD) Tops Q3 EPS by 1c

November 9, 2009 4:12 PM EST

Acadia Pharmaceuticals Inc. (NYSE: ACAD) reports a Q3 loss of $0.23, 1 cent better than the analyst estimate of ($0.24). Revenue for the quarter was $2.4 million, which compares to the estimate of $2 million.


Related Categories

Earnings

Stocks Mentioned

ACAD 1.34

+0.01 +0.75%
Volume: 252,967
Track ACAD


Add Your Comment